SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/11/1/57 |
id |
doaj-5571f74e02cf477f9d9b0de31dbdbce6 |
---|---|
record_format |
Article |
spelling |
doaj-5571f74e02cf477f9d9b0de31dbdbce62021-01-07T00:00:27ZengMDPI AGBrain Sciences2076-34252021-01-0111575710.3390/brainsci11010057SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s DiseaseAna Gómez-López0Arantxa Sánchez-Sánchez1Elena Natera-Villalba2Victoria Ros-Castelló3Álvaro Beltrán-Corbellini4Samira Fanjul-Arbós5Isabel Pareés Moreno6José Luis López-Sendon Moreno7Juan Carlos Martínez Castrillo8Araceli Alonso-Canovas9Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainNeurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, SpainBackground: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD.https://www.mdpi.com/2076-3425/11/1/57safinamideurinary symptomsParkinson diseasenonmotor fluctuations |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana Gómez-López Arantxa Sánchez-Sánchez Elena Natera-Villalba Victoria Ros-Castelló Álvaro Beltrán-Corbellini Samira Fanjul-Arbós Isabel Pareés Moreno José Luis López-Sendon Moreno Juan Carlos Martínez Castrillo Araceli Alonso-Canovas |
spellingShingle |
Ana Gómez-López Arantxa Sánchez-Sánchez Elena Natera-Villalba Victoria Ros-Castelló Álvaro Beltrán-Corbellini Samira Fanjul-Arbós Isabel Pareés Moreno José Luis López-Sendon Moreno Juan Carlos Martínez Castrillo Araceli Alonso-Canovas SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease Brain Sciences safinamide urinary symptoms Parkinson disease nonmotor fluctuations |
author_facet |
Ana Gómez-López Arantxa Sánchez-Sánchez Elena Natera-Villalba Victoria Ros-Castelló Álvaro Beltrán-Corbellini Samira Fanjul-Arbós Isabel Pareés Moreno José Luis López-Sendon Moreno Juan Carlos Martínez Castrillo Araceli Alonso-Canovas |
author_sort |
Ana Gómez-López |
title |
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_short |
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_full |
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_fullStr |
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_full_unstemmed |
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_sort |
surinpark: safinamide for urinary symptoms in parkinson’s disease |
publisher |
MDPI AG |
series |
Brain Sciences |
issn |
2076-3425 |
publishDate |
2021-01-01 |
description |
Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD. |
topic |
safinamide urinary symptoms Parkinson disease nonmotor fluctuations |
url |
https://www.mdpi.com/2076-3425/11/1/57 |
work_keys_str_mv |
AT anagomezlopez surinparksafinamideforurinarysymptomsinparkinsonsdisease AT arantxasanchezsanchez surinparksafinamideforurinarysymptomsinparkinsonsdisease AT elenanateravillalba surinparksafinamideforurinarysymptomsinparkinsonsdisease AT victoriaroscastello surinparksafinamideforurinarysymptomsinparkinsonsdisease AT alvarobeltrancorbellini surinparksafinamideforurinarysymptomsinparkinsonsdisease AT samirafanjularbos surinparksafinamideforurinarysymptomsinparkinsonsdisease AT isabelpareesmoreno surinparksafinamideforurinarysymptomsinparkinsonsdisease AT joseluislopezsendonmoreno surinparksafinamideforurinarysymptomsinparkinsonsdisease AT juancarlosmartinezcastrillo surinparksafinamideforurinarysymptomsinparkinsonsdisease AT aracelialonsocanovas surinparksafinamideforurinarysymptomsinparkinsonsdisease |
_version_ |
1724347104381370368 |